Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia Read more
Editas and BlueRock Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms Read more
Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases Read more
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients Read more